American Heart Journal

• 

  Publication Venue For

  • Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?.  239:11-18. 2021
  • African American-Caucasian American differences in aortic valve replacement in patients with severe aortic stenosis..  234:111-121. 2021
  • Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis..  233:59-67. 2021
  • Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis..  232:105-115. 2021
  • PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial..  223:98-105. 2020
  • Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation..  220:89-96. 2020
  • Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease (vol 206, pg 51, 2018).  216:150-150. 2019
  • Government continues to have an important role in promoting cardiovascular health..  198:160-165. 2018
  • Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the Randomized On/Off Bypass (ROOBY) trial..  198:33-38. 2018
  • Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction..  197:43-52. 2018
  • Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry..  174:29-36. 2016
  • Erratum: Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER): Implementing the patient-driven research paradigm to aid decision making in stroke care (Am Heart J (2014) 170 (36-45)).  170:615. 2015
  • Erratum: Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (American Heart Journal (2014) 169:1 (2530) DOI: 10.1016/j.ahj.2014.09.006).  169:594. 2015
  • Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.  169:496-507.e1. 2015
  • Results of the chronic heart failure intervention to improve medication adherence study: A randomized intervention in high-risk patients.  169:539-548. 2015
  • The making of an author.  169:446-447. 2015
  • Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (vol 169, pg 25, 2014).  169:594-594. 2015
  • Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction.  167:367-375.e2. 2014
  • Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease.  167:355-362.e3. 2014
  • Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry.  167:342-349.e17. 2014
  • The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.  167:335-341. 2014
  • Response to the clarification of the REMIT trial protocol.  164. 2012
  • Authors' reply to "the not so 'ideal' body weight-based dosing of Integrilin in obesity".  163. 2012
  • Authors' response to "a need, also, for transformative innovation in the definition of hypertension".  163. 2012
  • Treadmill testing improves survival prediction models in pulmonary arterial hypertension.  162:1011-1017. 2011
  • Current therapeutics and practical management strategies for pulmonary arterial hypertension.  162:201-213. 2011
  • Prospective assessment of the occurrence of anemia in patients with heart failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry (vol 157, pg 926, 2009).  158:77-77. 2009
  • Has American Heart Journal gone to the blogs?.  157:955-956. 2009
  • Lipid levels-in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines.  157. 2009
  • Late-breaking trials summary from the 2008 American College of Cardiology Scientific Sessions, March 29 to April 1, Chicago, IL.  156:7-12. 2008
  • Preventing tomorrow's sudden cardiac death today. Dissemination of effective therapies for sudden cardiac death prevention 2008
  • Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).  154:637-644. 2007
  • Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).  154:647-654. 2007
  • What we publish in the American Heart Journal and why.  154:1-2. 2007
  • Introduction.  153:1. 2007
  • Highlights from the 20th Scientific Sessions of the American Heart Association: November 12 to 15, 2006, Chicago, Illinois.  153:213-223. 2007
  • Highlights from the 55th Annual Scientific Sessions of the American College of Cardiology: March 11 to 14, 2006, Atlanta, Georgia.  151:1156-1172. 2006
  • Highlights from the American Heart Association Scientific Sessions, November 13 to 16, 2005, Dallas, TX.  151:295-307. 2006
  • Authors' reply.  152:e45. 2006
  • Discovery of proteins related to coronary artery disease using industrial scale proteomics analysis of pooled plasma (vol 152, pg 478, 2006).  152:1021-1021. 2006
  • Erratum: Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial ( American Heart Journal (2005) 150 (116-122) ).  150:391. 2005
  • Heart disease epidemic in Pakistan: women and men at equal risk..  150:221-226. 2005
  • Highlights from the American Heart Association Annual Scientific Sessions 2004: November 7-10, 2004.  149:240-253. 2005
  • Reply.  148:e4-e4. 2004
  • Erratum: Aborted infarction: The ultimate myocardial salvage (American Heart Journal (2004) 147 (390-394)).  147:684. 2004
  • Introduction of a new section: Cardiology Fellows - Quick Evidence-Based Consult.  147:1. 2004
  • The management of decompensated heart failure resulting in hospitalization: Proceedings from an expert meeting to review current concepts and to define future directions - Introduction.  145. 2003
  • Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.  143:725-732. 2002
  • Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.  143:753-759. 2002
  • Hyperlipidemia in children and adolescents..  142:433-439. 2001
  • Inotropic therapy for heart failure: an evidence-based approach..  142:393-401. 2001
  • Obesity and insulin resistance in young people..  142:440-444. 2001
  • Pounds of prevention: obesity therapy..  142:388-390. 2001
  • The role of reperfusion therapy in paced patients with acute myocardial infarction..  142:516-519. 2001
  • Cardiac conduction abnormalities in endocarditis defined by the Duke criteria..  142:280-285. 2001
  • Highlights from the American College of Cardiology Forty-Ninth Annual Scientific Sessions: March 18 to 21, 2001.  142:363-374. 2001
  • Predictors of costs of caring for elderly patients discharged with heart failure..  142:350-357. 2001
  • Primary renal artery stenting: characteristics and outcomes after 363 procedures..  142:314-323. 2001
  • The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy..  142:211-217. 2001
  • A tale of two countries: Insights from the differences in Canadian/American patterns of care for patients with acute coronary syndromes..  142:14-20. 2001
  • Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies..  142:7-13. 2001
  • Cardiac rehabilitation and survival in patients with left ventricular systolic dysfunction..  142:160-166. 2001
  • Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization..  142:72-74. 2001
  • Post-myocardial infarction risk stratification in elderly patients..  142:37-42. 2001
  • The emerging role of myoglobin for risk stratification..  142:4-6. 2001
  • The risk of stroke and death in patients with aortic and mitral valve endocarditis..  142:75-80. 2001
  • Aortic counterpulsation in acute myocardial infarction: physiologically important but does the patient benefit?.  141:889-892. 2001
  • Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST..  141:908-914. 2001
  • Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram..  141:915-924. 2001
  • Antithrombotic therapy after prosthetic cardiac valve implantation: improving postoperative, long-term patient management. Introduction..  141:847-848. 2001
  • The "ideal" replacement heart valve..  141:856-860. 2001
  • Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale..  141:528-535. 2001
  • Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal?.  141:331-333. 2001
  • Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy..  141:469-477. 2001
  • Troponin I in cardiac surgery: marking the future..  141:325-326. 2001
  • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention..  141:226-233. 2001
  • Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes..  141:190-199. 2001
  • Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes..  141:47-54. 2001
  • Data and safety monitoring committees: philosophy and practice..  141:154-155. 2001
  • Highlights from the American college of cardiology 50th annual scientific sessions: March 18 to 21, 2001 (vol 142, pg 363, 2001).  142:678-678. 2001
  • Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin.  141:1025-1037. 2001
  • Critical concepts in cost-effectiveness for cardiovascular specialists..  140:S143-S147. 2000
  • Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention..  140:834-839. 2000
  • Glycoprotein IIb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction..  140:S115-S124. 2000
  • New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience..  140:878-885. 2000
  • The congestion score: a simple tool for a complicated disease?.  140:824-826. 2000
  • Evaluation of early postoperative results after bicaval versus standard cardiac transplantation and review of the literature..  140:717-721. 2000
  • Myocarditis and long-term survival in peripartum cardiomyopathy..  140:785-791. 2000
  • Depression and ischemic heart disease..  140:63-69. 2000
  • Depression as a contributing factor in cerebrovascular disease..  140:70-76. 2000
  • Introduction..  140:55-56. 2000
  • Accuracy of three-dimensional echocardiography with unrestricted selection of imaging planes for measurement of left ventricular volumes and ejection fraction..  140:469-475. 2000
  • Cardiac marker testing: where should we focus?.  140:351-353. 2000
  • Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate..  140:385-394. 2000
  • Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin..  140:367-372. 2000
  • Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade..  140:74-80. 2000
  • Observations on the transition from intermittent to permanent atrial fibrillation..  140:142-145. 2000
  • Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the duke criteria..  139:945-951. 2000
  • Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial..  139:927-933. 2000
  • Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy..  139:962-970. 2000
  • Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics?.  139:745-751. 2000
  • Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS)..  139:820-823. 2000
  • Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts..  139:824-829. 2000
  • When is angina good? Preconditioning in acute myocardial infarction..  139:771-772. 2000
  • Acute ischemic heart disease..  139:S189-S192. 2000
  • Economic end points in phase II trials..  139:S155-S157. 2000
  • Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction..  139:567-576. 2000
  • Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors..  139:609-617. 2000
  • Sample size and interim analysis issues for dose selection..  139:S161-S165. 2000
  • Sex differences in coronary artery size assessed by intravascular ultrasound..  139:649-653. 2000
  • The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials..  139:S143-S154. 2000
  • Cardiology, for what it's worth..  139:392-393. 2000
  • Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials..  139:476-481. 2000
  • Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment..  139:S38-S45. 2000
  • Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network Database..  139:198-207. 2000
  • Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department..  139:320-328. 2000
  • Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series..  139:114-121. 2000
  • Correlates of high hdl cholesterol among women with coronary heart disease.  139:288-296. 2000
  • Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures..  139:106-113. 2000
  • Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. The ENRICHD investigators..  139:1-9. 2000
  • Evolving trends in interventional device use and outcomes: Results from the national cardiovascular network database.  139:198-207. 2000
  • Highlights from the American Heart Association 72nd Scientific Sessions: November 6 to 10, 1999.  139:359-370. 2000
  • Low-molecular-weight heparin as optimal solution to therapeutic heparinization [3] (multiple letters).  139:558-561. 2000
  • Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure..  139:15-22. 2000
  • Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department.  139:320-328. 2000
  • A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study..  138:1140-1148. 1999
  • Heart failure after myocardial infarction: A good heart is hard to find..  138:1009-1011. 1999
  • Hemostasis of the femoral vasculature: Shouldn't we have an answer by now?.  138:1014-1015. 1999
  • Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry..  138:1065-1072. 1999
  • Translation of clinical evidence into medical practice..  138:1001-1002. 1999
  • ASDOS closures: congratulations and technical observations..  138:808-809. 1999
  • Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies..  138:S406-S412. 1999
  • Comparison of outcome after coronary angioplasty and coronary surgery for multivessel coronary artery disease in persons with diabetes..  138:S394-S399. 1999
  • Effect of dofetilide on survival in patients with supraventricular arrhythmias..  138:994-997. 1999
  • Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience..  138:976-982. 1999
  • Insulin resistance syndrome and cardiovascular disease: genetics and connections to skeletal muscle function..  138:S413-S416. 1999
  • Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction..  138:S376-S380. 1999
  • A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes..  138:261-262. 1999
  • Assessing the severity of mitral stenosis: variability between noninvasive and invasive measurements in patients with symptomatic mitral valve stenosis..  138:777-784. 1999
  • Cardiac troponins in congestive heart failure..  138:646-653. 1999
  • Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure..  138:625-632. 1999
  • Mortality and need for reoperation in patients with mild-to-moderate asymptomatic aortic valve disease undergoing coronary artery bypass graft alone..  138:791-797. 1999
  • Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors..  138:317-326. 1999
  • Vale, warfarin: a stentorian farewell..  138:602-605. 1999
  • Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis..  138:533-539. 1999
  • Clinical features of Wolff-Parkinson-White syndrome..  138:403-413. 1999
  • Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries..  138:493-499. 1999
  • Practice still makes perfect..  138:394-395. 1999
  • Predictors of patient-reported physical and mental health 6 months after percutaneous coronary revascularization..  138:422-429. 1999
  • Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty..  138:376-383. 1999
  • Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee..  138:210-218. 1999
  • Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)..  138:78-86. 1999
  • Effect of clinical factors on length of stay after coronary artery bypass surgery: results of the cooperative cardiovascular project..  138:69-77. 1999
  • Highlights from the American College of Cardiology 48th Annual Scientific Sessions: March 7 to 10, 1999..  138:175-190. 1999
  • Insights into the contemporary epidemiology and outpatient management of congestive heart failure..  138:87-94. 1999
  • Readministration of abciximab: interim report of the ReoPro readministration registry..  138:S33-S38. 1999
  • Steroids for restenosis: strike three!.  138:3-4. 1999
  • Treatment of type III hyperlipoproteinemia..  138:17-18. 1999
  • An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial..  137:1100-1106. 1999
  • Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization..  137:1163-1168. 1999
  • Hemodynamic effects of new intra-aortic balloon counterpulsation timing methods in patients: a multicenter evaluation..  137:1129-1136. 1999
  • Diastolic dysfunction: old dog, new tricks..  137:777-778. 1999
  • Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy..  137:S90-S93. 1999
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis..  137:S38-S40. 1999
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis..  137:S47-S50. 1999
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data..  137:S123-S125. 1999
  • Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction..  137:792-798. 1999
  • Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators..  137:799-805. 1999
  • Real-time, three-dimensional echocardiography: feasibility of dynamic right ventricular volume measurement with saline contrast..  137:958-966. 1999
  • Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction..  137:612-620. 1999
  • The abbreviated life of acronyms..  137:577-578. 1999
  • Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease..  137:453-457. 1999
  • Highlights from the 71st American Heart Association Scientific Sessions: November 8 to 11, 1998..  137:555-574. 1999
  • Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators..  137:264-273. 1999
  • A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease.  137:59-71. 1999
  • Cardiopulmonary resuscitation: historical perspective to recent investigations..  137:39-48. 1999
  • Dealing with success at the American Heart Journal.  137:769. 1999
  • Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion..  137:12-23. 1999
  • Racial differences in the management of unstable angina: Results from the multicenter GUARANTEE registry.  138:1065-1072. 1999
  • Abnormal left ventricular filling after neonatal repair of congenital heart disease: association with increased mortality and morbidity..  136:1075-1080. 1998
  • Progression of renal artery stenosis in patients undergoing cardiac catheterization..  136:913-918. 1998
  • Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries..  136:868-876. 1998
  • Coagulation markers and outcomes in acute coronary syndromes..  136:S7-18. 1998
  • Doppler pressure half-time method of assessing mitral valve area: aortic insufficiency does not adversely affect validity..  136:718-723. 1998
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings..  136:S32-S42. 1998
  • Kissing stents in the aortic bifurcation..  136:600-605. 1998
  • Progress in point-of-care laboratory testing for assessing platelet function..  136:S51-S65. 1998
  • Relation between inhibition of platelet aggregation and clinical outcomes..  136:S43-S50. 1998
  • Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke..  136:703-713. 1998
  • Depression and social support in elderly patients with cardiac disease..  136:491-495. 1998
  • Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction..  136:398-405. 1998
  • Patient risk or physician practice: what factors drive resource use in unstable angina?.  136:365-367. 1998
  • Learning to suspect the unexpected: evaluating women with cardiac syndromes..  136:186-188. 1998
  • Post-procedure heparin: boon or burden?.  136:183-185. 1998
  • Specificity of electrocardiographic myocardial infarction screening criteria in patients with nonischemic cardiomyopathies..  136:314-319. 1998
  • Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?.  136:43-48. 1998
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998..  136:176-179. 1998
  • Squeezing the "value" from cost data..  136:1-3. 1998
  • Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure..  135:S264-S284. 1998
  • Current and novel pharmacologic approaches in advanced heart failure..  135:S249-S263. 1998
  • Outcomes and costs within a disease management program for advanced congestive heart failure..  135:S285-S292. 1998
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998..  135:1099-1114. 1998
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes..  135:S56-S66. 1998
  • Exertional dyspnea in heart failure: a symptom unrelated to pulmonary function at rest or during exercise. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group..  135:398-405. 1998
  • Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: A nationwide perspective of current clinical practice.  135:786-796. 1998
  • Improvement in the mechanical efficiency of walking: an explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group..  135:107-114. 1998
  • Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina..  135:10-14. 1998
  • Pathobiology of thrombin in acute coronary syndromes.  136:S19-S31. 1998
  • Session highlights from the American Heart Association Scientific Sessions: November 9-12, 1997..  135:157-180. 1998
  • Coronary artery bypass grafting in the elderly..  134:856-864. 1997
  • Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease..  134:S88-S96. 1997
  • Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy..  134:631-638. 1997
  • Stability over time of circadian rhythm of variability of heart rate in patients with stable coronary artery disease..  134:411-418. 1997
  • Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model..  133:663-673. 1997
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators..  133:630-639. 1997
  • The natural history of single-vessel chronic coronary occlusion: a 25-year experience..  133:393-399. 1997
  • TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis..  133:273-282. 1997
  • Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease.  134. 1997
  • Lessons for the editors.  134:1-2. 1997
  • Our vision for the American Heart Journal..  133:137-138. 1997
  • Vascular hypertrophy is an early finding in essential hypertension and is related to arterial pressure waveform contour..  132:621-627. 1996
  • Isolated innominate artery in asplenia syndrome with aortic atresia: newly recognized cardiovascular complex..  131:1042-1044. 1996
  • Comparison of thickness and distensibility in the carotid artery and descending thoracic aorta: in vivo ultrasound assessment..  131:655-662. 1996
  • Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated?.  131:796-813. 1996
  • Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction.  131:421-433. 1996
  • Optimal determination of right ventricular filling dynamics in systemic hypertension..  130:1074-1082. 1995
  • Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor..  130:877-892. 1995
  • Bilateral vitreous hemorrhages as a consequence of thrombolytic therapy successfully treated with vitrectomy in a patient without diabetes..  130:611-612. 1995
  • Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents..  130:673-679. 1995
  • Hypotension during dobutamine stress echocardiography: is it related to dynamic intraventricular obstruction?.  130:314-317. 1995
  • Does hypotension during dobutamine stress echocardiography correlate with anatomic or functional cardiac impairment?.  129:1121-1126. 1995
  • Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection..  129:821-823. 1995
  • Application of quantitative coronary angiography in a cineless environment: in vivo assessment of a fully automated system for clinical use..  129:300-306. 1995
  • Inherited restrictive cardiomyopathy in a 74-year-old woman: a case of Fabry's disease..  129:199-202. 1995
  • Pathobiology of atherosclerosis and plaque complications..  128:1300-1304. 1994
  • Ischemic hibernating myocardium demonstrated by positron emission tomography in anomalous origin of the left coronary artery from the pulmonary artery..  128:181-185. 1994
  • Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: A coronary care unit experience.  128:719-723. 1994
  • Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors.  128:997-1009. 1994
  • Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction..  126:819-826. 1993
  • Correlation of adenosine echocardiography and thallium scintigraphy..  125:1606-1613. 1993
  • The clinical spectrum of patients with aneurysms of the ascending aorta..  125:1380-1385. 1993
  • A comparison of heparin strategies after thrombolytic therapy.  126:750-752. 1993
  • Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: A theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock.  125:919-929. 1993
  • Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration.  126:11-14. 1993
  • Thermal-perfusion balloon coronary angioplasty: in vivo evaluation..  125:226-233. 1993
  • Aggressive clinical pattern of angina at restenosis following coronary angioplasty in unstable angina..  124:1174-1180. 1992
  • Early and late outcome following deployment of a new flexible tantalum intracoronary stent in dogs..  124:1058-1067. 1992
  • Coronary angioplasty performed with gradual and prolonged inflation using a perfusion balloon catheter: procedural success and restenosis rate..  124:585-589. 1992
  • Left ventricular function under stress before and after myocardial revascularization..  124:273-279. 1992
  • Combined rotational and directional atherectomy guided by intravascular ultrasound in an occluded vein graft..  124:214-216. 1992
  • Factors influencing immediate results, complications, and short-term follow-up status after Inoue balloon mitral valvotomy: a North American multicenter study..  124:160-166. 1992
  • Ten-year experience with mitral valve replacement in the elderly..  124:154-159. 1992
  • Acute termination of supraventricular tachycardia by adenosine during pregnancy..  123:1386-1388. 1992
  • Angiotensin-converting enzyme inhibition: research advances and clinical implications..  123:1412-1413. 1992
  • On the mechanism of action of antiarrhythmic agents..  123:1130-1136. 1992
  • Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism..  123:729-732. 1992
  • Recurrent myocardial ischemia following thrombolytic therapy: guidelines for practicing clinicians.  124:183-193. 1992
  • Reply.  123:1720. 1992
  • Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina..  122:949-954. 1991
  • The coronary artery response to implantation of a balloon-expandable flexible stent in the aspirin- and non-aspirin-treated swine model..  122:640-647. 1991
  • Detection of angiographically silent coronary atherosclerosis by intracoronary ultrasonography..  121:1803-1807. 1991
  • Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group..  121:1042-1049. 1991
  • Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement..  121:1244-1263. 1991
  • Acute fulminant myocarditis: long-term follow-up after circulatory support with left ventricular assist device..  121:922-926. 1991
  • The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group..  121:895-901. 1991
  • Adaptive and maladaptive cardiovascular responses in human sepsis.  122:1441-1448. 1991
  • Recent advances in the control of heart failure: Introduction.  121:950. 1991
  • Recombinant tissue-type plasminogen activator: Current concepts and guidelines for clinical use in acute myocardial infarction. Part I.  121:220-244. 1991
  • Recombinant tissue-type plasminogen activator: Current concepts and guidelines for clinical use in acute myocardial infarction. Part II.  121:627-640. 1991
  • The utility of echocardiography in the diagnostic strategy of postinfarction ventricular septal rupture: a comparison of two-dimensional echocardiography versus Doppler color flow imaging..  121:25-32. 1991
  • AV blockade via selective AV nodal artery injection in a patient..  120:986-988. 1990
  • Atrial septal aneurysm: recognition and clinical relevance..  120:948-957. 1990
  • Aspergillus myocarditis presenting as myocardial infarction with complete heart block..  120:430-432. 1990
  • One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial..  119:777-785. 1990
  • Serial evaluation of right ventricular dysfunction associated with acute inferior myocardial infarction..  119:816-822. 1990
  • Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group..  119:224-231. 1990
  • Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: A community-wide perspective.  119:996-1001. 1990
  • Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormality.  119:1254-1261. 1990
  • Serial evaluation of ventricular function after percutaneous aortic balloon valvuloplasty..  119:130-135. 1990
  • Validation of pressure-volume data obtained in patients by initial transit radionuclide angiocardiography..  118:983-989. 1989
  • Dissociation of ST segment elevation and regional wall motion with open-artery, intracoronary Fluosol..  118:679-685. 1989
  • Surgical repair of atrial septal defect in an 89-year-old man: progressive shunt due to concomitant aortic stenosis..  118:423-424. 1989
  • Early restenosis following successful percutaneous balloon valvuloplasty for calcific valvular aortic stenosis..  118:181-182. 1989
  • Transient reversal of bifascicular block during acute myocardial infarction with reperfusion therapy: a word of caution..  117:1381-1383. 1989
  • Utility of Doppler color flow imaging for identification of femoral arterial complications of cardiac catheterization..  117:623-628. 1989
  • Analysis of the early rise in aortic transvalvular gradient after aortic valvuloplasty..  117:411-417. 1989
  • Role of resting thallium201 perfusion in predicting coronary anatomy, left ventricular wall motion, and hospital outcome in unstable angina pectoris..  117:306-314. 1989
  • Interatrial septal thickening preventing percutaneous mitral valve balloon valvuloplasty..  117:206-210. 1989
  • Mechanism of the interaction of hypertension and hypercholesterolemia in atherogenesis: the effects of antihypertensive agents..  116:1725-1728. 1988
  • Inferior myocardial infarction complicated by mural thrombus and systemic embolization despite anticoagulation in progressive systemic sclerosis with normal coronary arteriograms..  116:1357-1359. 1988
  • Myocardial ischemia in constrictive pericarditis..  116:1107-1111. 1988
  • Electrocardiographic diagnosis of exercise-induced left ventricular hypertrophy..  116:784-790. 1988
  • Mitral stenosis: mitral dome excursion at M1 and the mitral opening snap--the concept of reciprocal heart sounds..  115:1280-1290. 1988
  • Electrocardiographic ST segment depression in coronary heart disease.  115:862-868. 1988
  • The decision to perform coronary bypass surgery in women. What are the facts?.  116:891-893. 1988
  • Congenital mitral insufficiency secondary to anomalous mitral arcade in an adult..  114:894-895. 1987
  • Dissociation between global and regional systolic and diastolic ventricular function during coronary occlusion and reperfusion..  114:687-695. 1987
  • Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias..  114:296-302. 1987
  • False aneurysm of the aortic root: mimic of malignancy, mediator of myocardial ischemia..  113:1237-1239. 1987
  • Validation of in vivo two-dimensional echocardiographic dimension measurements using myocardial mass estimates in dogs..  113:725-731. 1987
  • Ventricular arrhythmias during reperfusion..  112:928-932. 1986
  • Intraoperative assessment of left ventricular heterogeneity..  112:344-349. 1986
  • Percutaneous transluminal coronary angioplasty as palliation for patients considered poor surgical candidates..  111:840-844. 1986
  • Relative wall thickness analysis by two-dimensional echocardiography..  110:1012-1019. 1985
  • A reconsideration of Doppler assessed gradients in suspected aortic stenosis..  110:765-773. 1985
  • Effect of acute standing and prolonged upright activity on left ventricular hemodynamics, systolic and diastolic intervals, and QT-QS2 relationship..  110:623-630. 1985
  • A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response..  110:439-447. 1985
  • Coronary heart disease in black Americans: suggestions for research on psychosocial factors..  108:833-838. 1984
  • Socioeconomic influences on coronary heart disease in black populations..  108:669-672. 1984
  • Musical murmurs: clinical implications, long-term prognosis, and echo-phonocardiographic features..  108:377-386. 1984
  • Unimproved chest pain in patients with minimal or no coronary disease: a behavioral phenomenon..  108:67-72. 1984
  • Serial thallium-201 imaging at rest in patients with unstable and stable angina pectoris: relationship of myocardial perfusion at rest to presenting clinical syndrome..  106:70-77. 1983
  • QRS vector changes with rapid reduction of blood pressure in accelerated hypertension..  105:1038-1041. 1983
  • Detection of pulmonary venous flow by pulsed Doppler echocardiography in children..  105:826-829. 1983
  • Is it safe to use intravenous verapamil to treat a patient who is taking oral verapamil?.  105:329-331. 1983
  • Use of control steady-state serum digoxin levels for predicting serum digoxin concentration after quinidine administration..  104:72-76. 1982
  • Two-dimensional echocardiographic identification of sinus of Valsalva-right heart fistula due to infective endocarditis..  103:1068-1071. 1982
  • High prevalence of symptomatic bradyarrhythmias due to atrioventricular node-fascicular and sinus node-atrial disease in patients with mitral anular calcification..  103:226-229. 1982
  • Serial echographic development of apparent hypertrophic cardiomyopathy with biventricular outflow obstruction: documentation in Hemophilus influenzae pericarditis during hypovolemia..  102:1069-1071. 1981
  • M-mode echocardiographic observations in active bacterial endocarditis limited to the aortic valve..  102:66-75. 1981
  • DETECTION AND MECHANISMS OF ARRHYTHMOGENIC EPILEPSY - REPLY.  101:864-864. 1981
  • M-mode echocardiographic observations during and after healing of active bacterial endocarditis limited to the mitral valve..  101:37-45. 1981
  • Arrhythmogenic epilepsy: an hypothesis..  100:683-688. 1980
  • Histoplasma capsulatum endocarditis.  99:783-788. 1980
  • Effect of left anterior hemiblock on exercise-induced ST-T segment changes..  98:725-726. 1979
  • LDH isoenzymes and myocardial infarction in patients undergoing coronary bypass surgery: an excellent correlation..  92:584-588. 1976
  • Electrocardiographic and hemodynamic correlations in patients with idiopathic hypertrophic subaortic stenosis..  91:11-17. 1976
  • Complete and incomplete revascularization at aortocoronary bypass surgery: experience with 392 consecutive patients..  88:176-182. 1974
  • Antiarrhythmic drug action: selective depression of hypoxic cardiac cells..  87:602-605. 1974
  • Quantitative Frank vectorcardiograms of normal children and a comparison to those of patients with atrial defects..  83:332-339. 1972
  • Hypoplastic right lung with systemic blood supply and anomalous pulmonary venous drainage: reversal of pulmonary hypertension with surgical management in infancy..  83:82-88. 1972
  • Hypotensive effects of clonidine and chlorthalidone. Controlled clinical trial of drugs administered singly and in combination..  82:312-318. 1971
  • Hemodynamic effects of beta-adrenergic blockade at controlled ventricular rates..  76:775-783. 1968
  • Biplane cineangiographic determinations of left ventricular function: pressure-volume relationships..  74:766-779. 1967
  • Letter to the editor.  74:293-293. 1967
  • Body surface isopotential maps in normal children, ages 4 to 14 years..  72:640-652. 1966
  • A comparison of the electrical ventricular fibrillation threshold with and without anesthesia..  72:419-420. 1966
  • In response to the letter to the editor of Cikirikcioglu et al regarding "the EVEREST II Trial: Design and rationale for a randomized study of the Evalve MitraClip system compared with mitral valve surgery for mitral regurgitation".  162. 2011
  • Novel intravenous antithrombins..  141:1043-1047. 2001
  • Does pregnancy affect the durability of valvular bioprostheses?.  137:590-591. 1999
  • Efficacy of gadoversetamide enhanced MRI for the diagnosis and assessment of myocardial infarction: An international, multicenter, double-masked, randomized phase 2 trial 2005
  • "Ignorance region" of sensitivity and specificity of a diagnostic test when not all patients are verified with a gold standard 2002
  • Diabetes and ischemic heart disease. 1999